Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group
Stefano Giardino,Regis P de Latour,Mahmoud Aljurf,Dirk-Jan Eikema,Paul Bosman,Yves Bertrand,Abdelghani Tbakhi,Wolfgang Holter,Martin Bornhäuser,Claudia Rössig,Birgit Burkhardt,Marco Zecca,Boris Afanasyev,Gerard Michel,Arnold Ganser,Amal Alseraihy,Mouhab Ayas,Duygu Uckan-Cetinkaya,Benedicte Bruno,Katharine Patrick,Peter Bader,Maija Itälä-Remes,Vanderson Rocha,Charlotte Jubert,Miguel A Diaz,Peter J Shaw,Luiz G D Junior,Franco Locatelli,Nicolaus Kröger,Maura Faraci,Filomena Pierri,Edoardo Lanino,Maurizio Miano,Antonio Risitano,Marie Robin,Carlo Dufour,Severe Aplastic Anemia and Chronic Malignancies Working Parties of European Blood and Marrow Transplantation group
DOI: https://doi.org/10.1002/ajh.25810
Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo-HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre-HSCT cytoreductive therapies and related toxicities, disease status pre-HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome. The 5-year OS and EFS were 42% (30-53%) and 39% (27-51%), respectively. Patients transplanted in CR showed better OS compared with those transplanted in presence of an active malignant disease (OS:71%[48-95] vs 37% [24-50],P = .04), while none of the other variables considered had an impact. Twenty-two patients received pre-HSCT cytoreduction and 9/22 showed a grade 3-4 toxicity, without any lethal event or negative influence on survival after HSCT(OS:toxicity pre-HSCT 48% [20-75%] vs no-toxicity 51% [25-78%],P = .98). The cumulative incidence of day-100 grade II-IV a-GvHD and of 5-year c-GvHD were 38% (26-50%) and 40% (28-52%). Non-relapse-related mortality and incidence of relapse at 5-years were 40% (29-52%) and 21% (11-30%) respectively, without any significant impact of the tested variables. Causes of death were transplant-related events in most patients (34 out of the 42 deaths, 81%). This analysis confirms the poor outcome of transformed FA patients and identifies the importance of achieving CR pre-HSCT, suggesting that, in a newly diagnosed transformed FA patient, a cytoreductive approach pre-HSCT should be considered if a donor have been secured.